Navigation Links
Soligenix Announces Formation of Pediatric Crohn's Disease Medical Advisory Board
Date:10/11/2011

e subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, SGX201, SGX202, SGX203, RiVax™, and LPM, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the DSMB's recent determination disclosed in our Form 8-K dated September 15, 2011 recommending that Soligenix stop its confirmatory Phase 3 clinical trial of orBec® in acute GI GVHD and  the risk that: the FDA will  require that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec®
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
11. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... the t:slim® and t:flex™ Insulin Pumps, today announced the ... of its common stock at a price to the ... Tandem from this offering are expected to be $56.3 ... estimated offering expenses payable by Tandem. All of the ...
(Date:2/26/2015)... -- Mail-service and specialty pharmacies will save ... plans $23.3 billion over the next decade, according ... Association (PCMA). "Home delivery of traditional ... ways to reduce health costs," said PCMA President ... resist efforts to restrict these cost-saving tools." ...
(Date:2/26/2015)... , Feb. 26, 2015  BD Life Sciences, a ... BDX ), a leading global medical ... focused on enabling high-resolution biology, today announced that ... for highly multiplexed cell isolation and single-cell gene ... BD,s powerful BD FACS™ single-cell sorting instrumentation and ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3
... Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel ... it has received financial support totaling $1.1 million from ... community. Halo will use the funds to expedite ... drug candidate for Duchenne muscular dystrophy (DMD). HT-100, ...
... 22, 2012  Unigene Laboratories, Inc. (OTCBB: UGNE) ... and development of peptide-based therapeutics today reported positive ... and dogs for its lead proprietary anorexigenic peptide, ... peptide selectively targeting the amylin receptor, is under ...
Cached Medicine Technology:Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 2Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100 3Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 2Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 3Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 4Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies 5
(Date:2/27/2015)... UT (PRWEB) February 27, 2015 ... Worst Commuter Cities in Florida " report today. ... from the 2013 U.S. Census Bureau survey, considering ... the time of the survey. , The report ... including methods of commuting and a breakdown of ...
(Date:2/27/2015)... February 27, 2015 With support from Google, ... Days at MoMath, a new collaboration offering Title I schools ... math museum in North America on ten days over the ... grades 6-8 from seven schools in the Bronx and Queens ... learning. , MoMath strives to fulfill the incredible demand for ...
(Date:2/27/2015)... February 27, 2015 The decision to relocate ... newer facilities and to make camp more accessible to campers ... for a Contact Football Camp. The fields are in premier ... the country,” states Mike de Surville, vice president of US ... comprised of experienced coaches with the passion to create a ...
(Date:2/27/2015)... With Spring’s wet weather on the way, it is important ... in mind. The latest article from Clean Crawls ... space conditions and repairs. , Clean Crawls begins their ... as to how water is getting into their crawl spaces. ... is through cracks in the foundation, walls, ceiling, or floor ...
(Date:2/27/2015)... Oklahoma (PRWEB) February 27, 2015 ... by the U.S. Drug Enforcement Agency (DEA). ... local organizations continue to utilize the “Take-Back” guidelines ... by the FDA. , Eufaula Prescription Drug Disposal ... 1425 Industrial Drive in Eufaula, Oklahoma as the ...
Breaking Medicine News(10 mins):Health News:40 Best and Worst Commuter Cities in Florida Announced by Obrella 2Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 2Health News:National Museum of Mathematics and Google Collaborate to Offer Cost-Free Field Trip Days for Title I Schools in NYC 3Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:Crawl Space FAQs are Answered in Clean Crawls Latest Article 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 2Health News:Narconon Arrowhead Promotes Local Prescription Drug Take Back Day 3
... HealthDay Reporter , TUESDAY, March 13 (HealthDay News) -- The ... like race, age and where they live, and can be ... study. Researchers analyzed food questionnaires from a large group ... the continental United States, with a focus on southeastern states. ...
... (March 13, 2012) Scientists have identified a new compound ... common form of liver cancer and fifth most common ... Qunolinone Inhibitor 1 (FQI1), works by inhibiting an oncogene ... Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar at Virginia Commonwealth ...
... , SATURDAY, March 10 (HealthDay News) -- ... last long after typical head injury symptoms disappear, researchers ... link to physical function could help improve treatment for ... the University of Kentucky, who led the study as ...
... (HealthDay News) -- The drug misoprostol reduced major complications ... a new study. Doctors often use misoprostol for ... now, however, there were no studies large enough to ... complications, either immediate or delayed, according to background information ...
... 2012 Research published today in the New England ... for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) ... a strong immune response and a favorable clinical outcome in ... cancer. The size of both the tumor that was ...
... Kathleen Doheny HealthDay Reporter , WEDNESDAY, March ... may decrease women,s risk of developing multiple sclerosis. ... of risk [of developing MS symptoms]," said study author ... and research group at Murdoch Children,s Research Institute in ...
Cached Medicine News:Health News:Race, Location Big Factors in American Diets 2Health News:Race, Location Big Factors in American Diets 3Health News:New compound discovered that rapidly kills liver cancer 2Health News:'Delayed Reactions' May Outlast Other Concussion Effects 2Health News:Drug Reduces Complications in Surgical Abortions: Study 2Health News:NEJM study shows combination treatments benefit melanoma patient 2Health News:Pregnancy May Protect Against MS, Study Says 2
... replacement of chordae tendineae is a critical, ... used successfully in chordae tendineae procedures for ... ePTFE, nonabsorbable monofilament suture available with a ... suture also is provided with thin ePTFE ...
... Whether for bypass grafting or creation of ... placed tissue tunnel is of the utmost ... is the answer for those seeking a ... configuration minimizes the risk of twisting or ...
... Grafts have met the challenges of ... for exceptional performance and quality, they ... surgeons worldwide. These grafts require no ... of infection, and ensure utmost thrombectomy ...
... Vascular Grafts have met the challenges ... Recognized for exceptional performance and quality, ... renowned surgeons worldwide. These grafts require ... spread of infection, and ensure utmost ...
Medicine Products: